Navigation Links
Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
Date:12/13/2011

RICHMOND, Calif., Dec. 13, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the presentation of new data demonstrating the ability to permanently correct a disease gene in an adult mouse model of hemophilia B using systemic delivery of zinc finger nucleases (ZFNs) at the 53nd Annual Meeting of the American Society of Hematology (ASH).

"We have demonstrated functional correction of a human gene for the clotting factor, Factor IX, with a single, systemic administration of ZFNs in an animal model of disease," said Geoff Nichol, M.B, Ch.B., Sangamo's executive vice president of research and development.  "Our approach enables permanent correction of the genetic defect responsible for hemophilia B.  This circumvents the problems of traditional gene-addition approaches that uncouple the gene from its normal regulatory mechanism and which may result in gene silencing and random gene insertion and potentially lead to malignancy or other unintended consequences."

Abst. No.668 - Robust Factor IX Expression Following ZFN-mediated Genome Editing in an Adult Mouse Model of Hemophilia B (Oral Session: 801)

In this study, scientists demonstrated efficient ZFN-mediated gene correction in an adult mouse model of hemophilia B with a single systemic administration of ZFNs and a donor DNA sequence encoding the corrected human Factor IX gene. Stable levels of protein made from the corrected human gene could be measured in the plasma of the treated animals and resulted in the restoration of normal rates of blood clotting for the period of the study.  This work expands upon earlier studies, published in Nature*, that demonstrated similar results in neonatal mice.  Data described at the ASH meeting demonstrate that growth of liver cells, as is observed in neonates, is not required for efficient
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Sangamo BioSciences Announces Presentation at the Lazard Capital Markets 8th Annual Healthcare Conference
2. Sangamo BioSciences Reports Third Quarter 2011 Financial Results
3. Sangamo BioSciences Announces Third Quarter 2011 Conference Call and Webcast
4. Sangamo BioSciences Announces Presentation at the 18th Annual Newsmakers in the Biotech Industry Conference
5. Sangamo BioSciences Announces Presentation at the 2011 UBS Global Life Sciences Conference
6. Sangamo BioSciences Reports Second Quarter 2011 Financial Results
7. Sangamo BioSciences Announces Efficient Generation of Transgenic Pigs Using Zinc Finger Nuclease (ZFN) Technology
8. Sangamo BioSciences Announces Second Quarter 2011 Conference Call and Webcast
9. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
10. Sangamo Announces Pricing of Public Offering of Common Stock
11. Sangamo Announces Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... The Pittcon 2015 Exposition, which ... N. Morial Convention Center in New Orleans, Louisiana, ... 19, 2015) displaying products and services used by ... labs. The Exposition will offer the latest innovations ... analytical chemistry; drug discovery; nanotechnology; life sciences to ...
(Date:2/26/2015)... Innovation is more urgent than ever. ... of the world and transforming global markets in ... to health care, disruption is constantly underway. , ... trends shake the foundations of established business models, ... to survive the next wave of mega-change. , ...
(Date:2/26/2015)... February 26, 2015 According to a ... Biotechnology Market For Transgenic Crops (Corn, Soybean, Cotton and ... Analysis, Size, Share, Growth, Trends and Forecast, 2013 – ... 15,300 million in 2012 and is expected to reach ... of 9.5% from 2013 to 2019. , Demand ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 Regis Technologies ... the development of oncology drug substances. , Regis Technologies ... of their new Potent Compound Suite (PCS) for 2015. ... 36,000 square foot, cGMP facility in Morton Grove, Illinois. ... manufacturing of potent compounds up to about one kilogram ...
Breaking Biology Technology:Pittcon 2015 Announces Exposition Highlights 2One Million Acts of Innovation Canada Creates Partnership with The Economist Events’ Innovation Forum 2Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 2Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 3Regis Extends cGMP Services to Oncology Market 2
... EMERYVILLE, Calif., April 20 Bionovo, Inc. (Nasdaq: ... data on the nature of the active compound and mechanism ... presentation is being made at the 2009 conference of the ... the study concludes the following:, , ...
... Physicians Join World Class Group of AdvisorsSAN DIEGO, April ... of its Clinical Advisory Board, naming Donald H. Batts, ... the sixth and seventh members of the group of ... of Medicine at Michigan State University and ...
... dermatology company, acquired by GSK in deal valued ... have combined revenues of approximately $1.5 billion and ... and diversify GSK,s business, providing immediate new revenue ... (NYSE: GSK ) and Stiefel Laboratories ...
Cached Biology Technology:Bionovo Announces Publication of Data on Active Compound and Mechanism of Action for Its Preclinical Cancer Treatment, BN108 2Bionovo Announces Publication of Data on Active Compound and Mechanism of Action for Its Preclinical Cancer Treatment, BN108 3Trius Appoints Don Batts and Ralph Corey to Clinical Advisory Board 2GlaxoSmithKline and Stiefel to Create New World-Leading Specialist Dermatology Business 2GlaxoSmithKline and Stiefel to Create New World-Leading Specialist Dermatology Business 3GlaxoSmithKline and Stiefel to Create New World-Leading Specialist Dermatology Business 4
(Date:2/18/2015)... 18, 2015  Cepheid (NASDAQ: CPHD ) today ... conferences, and invited investors to participate via webcast. , ... Tuesday, March 3, 2015 at 11.20 a.m. Eastern ... Orlando, FL Wednesday, March 4, 2015 at 10.25 ... the live webcasts for these events, please visit Cepheid,s website ...
(Date:2/10/2015)... 10, 2015  Alere Inc. (NYSE: ALR), a ... results for the quarter ended December 31, 2014. ... President of Alere said, "We made substantial progress ... the global leader in rapid diagnostics and delivering ... Health divestiture in early January enabled us to ...
(Date:2/5/2015)... Jan. 26, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... ( http://www.nxt-id.com/ ) as part of its 2015 marketing ... Company launched its new consumer website for Wocketwallet.com earlier ... CEO of NXT-ID said, "Our new corporate website naturally ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34Alere Inc. Announces Fourth Quarter 2014 Results 35
... is on the rise and may be problematic, according ... the December issue of Obstetrics & Gynecology, Erin Tracy, ... and may present potential pitfalls for patients and physicians. ... have no proven clinical validity whatsoever and are quite ...
... for advanced age-related macular degeneration, researchers from Harvard and ... the cure. A research report published in the December ... endostatin to mice significantly reduced or eliminated abnormal blood ... the disease causes blindness. Our study provides ...
... brain injury and using club drugs have in common" ... chemical chain reaction in the brain, leading to cell death, ... series of studies at UF over the past five years ... MDMA, and other forms of methamphetamine lead to the same ...
Cached Biology News:Direct-to-consumer advertising for genetic tests concerns physicians and may mislead patients 2New treatment for age-related macular degeneration within sight 2Club drugs inflict damage similar to traumatic brain injury 2Club drugs inflict damage similar to traumatic brain injury 3
... all types of yeast two-hybrid studies, including complex interaction ... Choice of two bait vectors for maximum flexibility ... Triple reporter strain NMY51 ensures ... Complete set of controls: pLexA-p53, pLexA-lamin C ...
... labware. Waterproof, moisture-proof film prevents sample ... be folded repeatedly and twisted around ... at 21C (70F), wrapping film increases ... removed, film only partially returns to ...
Human Serum FDA Licensed US Donor Centers Sterile / Non-sterile: Sterile Filtered to 0.2 micron Information: Extensive Viral Testing ...
Normal human serum collected off the clot from healthy normal humans. Each donor unit is negative for anti-HIV 1&2, HIV-Ag, HCV, and HBsAg by FDA required tests...
Biology Products: